Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule
Company Will Provide New Interim Data for Pegzilarginase in Patients with Arginase 1 Deficiency Preclinical Efficacy Data of AEB4104 - a New Enzyme Approach - for the treatment of Homocystinuria Three-Conference Schedule Includes Five Abstract Acceptances Regarding Rare Genetic Disease and Cancer
Toggle Summary Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
AUSTIN, Texas , July 19, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Anthony G.
Toggle Summary Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
AUSTIN, Texas , July 16, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Bryan Lawlis ,
Toggle Summary Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas , June 29, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that the Compensation Committee of
Toggle Summary Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference
Company to Webcast Presentation on Tuesday, May 22 at 8:30 a.m. ET AUSTIN, Texas , May 15, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
AUSTIN, Texas , May 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today provided a corporate update and reported
Toggle Summary Aeglea BioTherapeutics Prices Public Offering of Common Stock
AUSTIN, Texas , April 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the pricing of its underwritten
Toggle Summary Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas , April 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it has commenced an
Toggle Summary Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
Clinical Outcome Assessment Tools Detected and Quantified Baseline Abnormalities Clinically Relevant Improvement Seen in Multiple Neuromotor Tests Company to Host Clinical Update Conference Call Today at 8:30 a.m. ET AUSTIN, Texas , April 12, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
AUSTIN, Texas , April 05, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present Phase 1 dose
Toggle Summary Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
Company to Host Clinical Update Conference Call on April 12 at 8:30 a.m. ET AUSTIN, Texas , April 03, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
Topline Safety and Clinical Activity Phase 1 Data Expected in 4Q 2018 AUSTIN, Texas , April 02, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Appoints Dr. Ivana Magovčević-Liebisch to Board of Directors
AUSTIN, Texas , March 26, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Ivana
Toggle Summary Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
Company to Webcast Presentation on Tuesday, March 27 at 9:00 a.m. ET AUSTIN, Texas , March 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results
Repeat Doses of Company’s Pegzilarginase Produces Marked and Sustained Reductions in Plasma Arginine Levels      Accompanying Reductions in Other Related Guanidino Compounds Also Seen  Additional Arginase 1 Deficiency Clinical Data in April at 2018 ACMG Annual Clinical Genetics Meeting Clinical and